Please fax both pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Ulcerative Colitis



Four simple steps to submit your referral.

New patient Current patien	t							
Patient's first name			Last name			Middle initia	al	
Preferred patient first name								
·				·				
Date of birthSt	-				_			
City		St	ate		Zip			
Home phone	Cell p	hone		_ Email address				
Parent/guardian (if applicable)								
Home phone	Cell p	hone		_ Email address				
Alternate caregiver/contact								
Home phone	Cell p	hone		_ Email address				
OK to leave message with altern	ate caregiver/co	ntact						
Patient's primary language: Eng	glish Other	If other, please	e specify					
2 Prescriber Infor				nust be completed to				
Office/clinic/institution name								
Prescriber info: Prescriber's first na								
Prescriber's title								
Office phone								
Office contact and title								
Office street address								
City								
Infusion location: Patient's home								
Infusion info: Infusion site name _			Clinic/	hospital affiliation				
Site street address					Suit	te #		
City		S	State			Zip		
nfusion site contact		_ Phone	Fa	κ Ι	Email			
3 Clinical Informa	ntion							
Primary ICD-10 code (REQUIRED):			Has the patie	nt been treated previo	usly for this c	ondition?	Yes	No
Is patient currently on therapy?	Yes No Ple	ease list all there	apies tried/failed:					
Detient of	D-t- 1 11	ta a d						
Patient wt NKDA Known drug allergies								
Concurrent meds								

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

Prescribing Information

Medication	Strength/Formulation	Directions	Quantity/Refills	
Simponi® (golimumab)	100mg/mL in each single-dose prefilled syringe (PFS) 100mg/mL in each single-dose pen	Loading dose: Inject 200mg subcutaneously at week 0, followed by 100mg subcutaneously at week 2	QS for 42-day supply loading dose No Refills	
		Maintenance dose: Inject 100mg subcutaneously every 4 weeks.	1-month supply 3-month supply Refill QS 1 year unless otherwise noted Other	
Stelara® (ustekinumab)	90mg/mL in each single-dose PFS	Maintenance dose: Inject 90mg subcutaneously every 8 weeks.	1-month supply 3-month supply Refill QS 1 year unless otherwise noted Other	
		Maintenance Dose Only Needed. If loading dose is needed, ple Stelara on this form, I am indicating that patient has already re at this time.		
Xeljanz®	10mg tablets	Loading dose:	QS for 2-month loading dose	
Acijanz	Tonig tablets	Take 10mg by mouth twice daily for 8 weeks, followed by 5mg twice daily	No Refills	
	5mg tablets 10mg tablets	Maintenance dose: Take 10mg by mouth twice daily Take 5mg by mouth twice daily Take 5mg by mouth once daily	1-month supply 3-month supply Refill QS 1 year unless otherwise noted Other	
Xeljanz XR™	22mg ER tablets	Loading dose: 22mg once daily for at least 8 weeks, followed by 11mg once daily	QS for 2-month loading dose No Refills	
	11mg ER tablets	Maintenance dose: Take 11mg by mouth once daily	1-month supply 3-month supply Refill QS 1 year unless otherwise noted Other	
Zeposia® (ozanimod)	Starter dose: Starter Pack (28 day) Starter Pack (7 day)	Take one 0.23mg capsule daily for 4 days, then one 0.46mg capsule for 3 days, then one 0.92mg capsule daily thereafter	1 kit No Refills	
	Maintenance dose: 0.92mg capsules	Take one capsule daily	1-month supply 3-month supply Refill QS 1 year unless otherwise noted Other	
Other				

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE	•			
TILIL	Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

